EpiEndo commences Phase 2a trial for EP395 in COPD patients

Regulatory approval for first patient study of first non-antibiotic macrolide REYKJAVIK, Iceland–(BUSINESS WIRE)–EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients. EP395 is an orally available macrolide or ‘Barriolide™,’ … [Read more…]

Dexcom Invites the Diabetes Community to #seediabetes This November and Share Their Diabetes Story With Custom Continuous Glucose Monitor (CGM) Patches

Dexcom Warriors Henry Slade, Roxy Horner, Sheku Kanneh-Mason and Eoin Costelloe unveil their custom Dexcom continuous glucose monitor (CGM) patches to tell their ‘Diabetes Story’ On World Diabetes Day and throughout the month of November, people with diabetes and their support systems are banding together around the globe to help the diabetes community feel more … [Read more…]

Middle East Healthcare Community Reunites in Saudi Arabia to Reimagine Health at HIMSS22 Middle East

RIYADH, Saudi Arabia–(BUSINESS WIRE)–The Middle East’s digital health transformation will be at the top of mind for healthcare and IT leaders at the 2022 HIMSS Middle East Health Conference & Exhibition in mid-November. Healthcare Information and Management Systems Society will convene health professionals in Riyadh, Saudi Arabia, from 19 to 21 November 2022 for world-class … [Read more…]

Medimaps Group Announces Partnership With OsteoSys to Bring Trabecular Bone Score to Korea’s Leading Bone Densitometry Platform

GENEVA–(BUSINESS WIRE)–#BMD—MEDIMAPS GROUP (www.medimapsgroup.com), a Swiss/Global med-tech company specializing in image processing software for assessing bone health, today announced that its novel method for enhancing osteoporotic fracture risk assessment, Trabecular Bone Score (TBS iNsight™), a surrogate of bone microarchitecture boosted by AI, is now available on diagnostic platforms from OsteoSys Co., Ltd. OsteoSys is the … [Read more…]

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer

Based on DESTINY-Gastric02, which showed Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated clinically meaningful efficacy and DESTINY-Gastric01, which showed improved overall survival compared to chemotherapy TOKYO & MUNICH–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of … [Read more…]

Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022

Winning paper demonstrates potential of vectorized novel CTLA-4 targeting antibodies and was highlighted at SITC 2022 Reaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent currently in a Phase I/IIa trial STRASBOURG, France–(BUSINESS WIRE)–$TNG–Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and … [Read more…]

Jabil Opens New Design Center to Support Sector Growth

WROCLAW, Poland–(BUSINESS WIRE)–Jabil Inc. (NYSE: JBL) has officially opened a new design center in Wroclaw, Poland, that will develop leading-edge technologies for multiple industries including the automotive and healthcare sectors. The opening of the 10,000 square foot center will provide a number of highly skilled engineering jobs and extends Jabil’s design capabilities in concept feasibility, … [Read more…]

Genentech Provides Update on Phase III GRADUATE Program Evaluating Gantenerumab in Early Alzheimer’s Disease

– Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer’s – – The level of beta-amyloid removal by gantenerumab was lower than expected – – Topline data will be presented at the Clinical Trials on Alzheimer’s Disease Conference – – Genentech is committed to the … [Read more…]

Innate Pharma Reports Third Quarter Financial Results

Preliminary data from ongoing Phase 2 TELLOMAK trial of lacutamab demonstrated clinical activity in mycosis fungoides, presented at EORTC-CLTG annual meeting Preliminary Sezary syndrome lacutamab Phase 2 data to be presented at ASH 2022 Annual Congress Innovative ANKET™ pipeline will be on display at ASH 2022 Annual Congress Cash position of €151.4 million1 as of … [Read more…]

World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China.

GALWAY, Ireland–(BUSINESS WIRE)–Late in 2021, Aerogen® (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia Air™ utilizing Aerogen’s proprietary aerosol drug delivery technology. In 2022 Convidecia Air™ was granted Emergency Use Authorization as a booster dose … [Read more…]